Benefits of Insoles With Real-Time Alert and Foot Self-Care Education
1 other identifier
interventional
72
1 country
2
Brief Summary
Novel approaches to promote adherence to diabetic footwear and prevent high incidence of diabetes foot ulcers are urgently needed. Investigators propose to translate an innovative and practical technology to supplement clinical and risk evaluation for patients with diabetes through wearable insoles and smart watch, along with foot self-care education, to improve adherence to prescribed footwear and reduce incidence of foot ulcers in those with diabetes and at risk for foot ulcers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2026
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 13, 2021
CompletedFirst Posted
Study publicly available on registry
October 12, 2021
CompletedStudy Start
First participant enrolled
October 20, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2026
Study Completion
Last participant's last visit for all outcomes
December 30, 2026
April 16, 2025
April 1, 2025
1 month
August 13, 2021
April 11, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
A Change in Adherence to prescribed footwear is being assessed
Daily adherence will be track by Sensor Data and Self-Report Questionnaire. The real-time alert component of the smart insoles will be measured by the tagging of patients' diabetes shoes by Orthimeter (Germany). The system has 1-year battery life and enables continuous measuring adherence to footwear by measuring temperature. Participants will be required to record number of days adhered to footwear or alerts.
2 months, 4 months and 6 months
Secondary Outcomes (3)
A change in Response Rate to Alert and Unreported Alert Duration is being assessed
2 months, 4 months and 6 months
A change in Foot Self-Care knowledge is being assessed
Baseline and 6 months
A change in Perception of Benefits is being assessed
2 months, 4 months and 6 months.
Other Outcomes (4)
A change in Adherence to device wear is being assessed
2 months, 4 months and 6 months
A change in Foot Ulcers is being assessed
Baseline and 6 months
A change in Off loading is being assessed
2 months, 4 months, and 6 months
- +1 more other outcomes
Study Arms (3)
Smart insoles + Education
EXPERIMENTALParticipants in this group will receive a 90-minute group session education on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch)
Smart Insoles
NO INTERVENTIONParticipants in this group will not receive a 90-minute group session education on foot self-care, but will receive foot care supplies, insoles and smart watch
Usual Care
NO INTERVENTIONParticipants will not receive foot self-care education or the use of insoles and smart watch.
Interventions
A 90-minute group session to educate patients on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch). Follow-up Care: A biweekly 30-minute one-on-one follow-up phone discussion (i.e., daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch, addressing feedback and questions regarding the intervention and prevention of foot-related complications).
Eligibility Criteria
You may qualify if:
- Men or women 18 years old or older,
- Diagnosis of Diabetes Mellitus,
- Ambulatory, Uses prescribed diabetes footwear.
- Those willing and able to attend follow up visits such as long distance (i.e. greater than 30 miles to recruitment sites).
- Those able to read or follow directions.
You may not qualify if:
- Active Charcot Arthropathy or major foot deformity,
- Cardiopulmonary disease (e.g. recent MI, Stroke),
- Gangrene, active infection. Montreal Cognitive Assessment (MOCA\<20).
- Wide spread malignancy or systemically immunocompromising disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Baylor College of Medicine
Houston, Texas, 77030, United States
Texas Woman's University
Houston, Texas, 77030, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ngozi Mbue
Texas Woman's University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 13, 2021
First Posted
October 12, 2021
Study Start (Estimated)
October 20, 2026
Primary Completion (Estimated)
November 30, 2026
Study Completion (Estimated)
December 30, 2026
Last Updated
April 16, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share